GenomeFrontier Therapeutics, Inc. Our mission is to develop next-generation gene therapies, aiming to achieve groundbreaking advancements in the field. As a company driven by innovation, we have harnessed four proprietary virus-free gene and cell engineering platforms, resulting in the creation of our robust cell-engineering Quantum Engine™ system.

With our Quantum Engine™, we have the potential to revolutionize the treatment of a wide range of diseases, including cancer. We are actively developing genetically reprogrammed T cells, namely Chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T), for adoptive immune cell therapy. CAR-T cells are designed to recognize specific antigens on the surface of cells, while TCR-T cells target endogenous antigens presented within the context of human leukocyte antigen (HLA).

Using the Quantum Engine™, we are currently working on the development of several CAR-T and TCR-T cell products for cancer treatment. Our cutting-edge technology and passion for innovation position us as leaders in the field of gene therapy, continuously pushing boundaries to improve patients' lives